Drugs that contain Buprenorphine Hydrochloride
1. Belbuca patents expiration
Can you believe BELBUCA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6159498 | BDSI | Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces |
Oct, 2016
(7 years ago) | |
| US7579019 | BDSI | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
Jan, 2020
(4 years ago) | |
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| US9901539 | BDSI | Transmucosal drug delivery devices for use in chronic pain relief |
Dec, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 23, 2018 |
Market Authorisation Date: 23 October, 2015
Treatment: Treatment of pain by transmucosal delivery of buprenorphine; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options...
Dosage: FILM;BUCCAL
How can I launch a generic of BELBUCA before it's drug patent expiration?
More Information on Dosage
BELBUCA family patents
2. Probuphine patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7736665 | TITAN PHARMS | Implantable polymeric device for sustained release of buprenorphine |
Apr, 2024
(41 minutes ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 26, 2019 |
Market Authorisation Date: 26 May, 2016
Treatment: For opioid dependence
Dosage: IMPLANT;IMPLANTATION
More Information on Dosage
PROBUPHINE family patents